Filtered By:
Condition: Pulmonary Hypertension
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 621 results found since Jan 2013.
Variations and characteristics of the various clinical phenotypes in a cohort of Nigerian sickle cell patients
CONCLUSION: The prevalence of SLU, AVN, priapism, nephropathy and the other complications of SCD show some variations from other studies. This variation in the clinical parameters across different clinical phenotypes indicates an interplay between age, genetic and environmental factors.PMID:34493173 | DOI:10.1080/16078454.2021.1972242
Source: Hematology - September 8, 2021 Category: Hematology Authors: Augustine Duru Anazoeze Jude Madu Helen Okoye Charles Nonyelu Onochie Obodo Kelechi Okereke Kenechi Madu Source Type: research
Right ventricular and cyclic guanosine monophosphate signalling abnormalities in stages B and C of heart failure with preserved ejection fraction
ConclusionExercise CMR identifies impaired RV-arterial coupling at an early stage of HFpEF. Circulating cGMP levels phenocopy the haemodynamic spectrum in HFpEF but fail to increase after phosphodiesterase type 5 inhibition, endorsing the need for alternative interventions to increase cGMP signalling in HFpEF.
Source: ESC Heart Failure - September 3, 2021 Category: Cardiology Authors: Thibault Petit,
Guido Claessen,
Mathias Claeys,
Andre La Gerche,
Piet Claus,
Stefan Ghysels,
Marion Delcroix,
Agnieszka Ciarka,
Walter Droogne,
Johan Van Cleemput,
Rik Willems,
Jens ‐Uwe Voigt,
Jan Bogaert,
Stefan Janssens Tags: Original Research Article Source Type: research
Surgical Treatment of Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension
Curr Pharm Des. 2021 Sep 2. doi: 10.2174/1381612827666210902152539. Online ahead of print.ABSTRACTVenous thromboembolism clinically presents as deep venous thrombosis or acute pulmonary embolism and is globally recognized as the third most frequent acute cardiovascular syndrome after myocardial infarction and stroke. Although pulmonary embolism does not typically cause severe pulmonary hypertension in the acute setting, thrombus organization and fibrosis can lead to stenosis or obliteration of pulmonary arteries in a minority of patients, which in turn result in severe pulmonary hypertension and right heart failure. This d...
Source: Current Pharmaceutical Design - September 3, 2021 Category: Drugs & Pharmacology Authors: Nikolaos Papakonstantinou Polydoros Kampaktsis Filippos-Paschalis Rorris Ilias Doulamis Aspasia Tzani Sotirios Katsaridis Dimitrios Avgerinos Source Type: research
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease,” sai...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Circulation. 2021 Jun 21:CIR0000000000000988. doi: 10.1161/CIR.0000000000000988. Online ahead of print.ABSTRACTObstructive sleep apnea (OSA) is characterized by recurrent complete and partial upper airway obstructive events, resulting in intermittent hypoxemia, autonomic fluctuation, and sleep fragmentation. Approximately 34% and 17% of middle-aged men and women, respectively, meet the diagnostic criteria for OSA. Sleep disturbances are common and underdiagnosed among middle-aged and older adults, and the prevalence varies by race/ethnicity, sex, and obesity status. OSA prevalence is as high as 40% to 80% in patients with ...
Source: Circulation - June 21, 2021 Category: Cardiology Authors: Yerem Yeghiazarians Hani Jneid Jeremy R Tietjens Susan Redline Devin L Brown Nabil El-Sherif Reena Mehra Biykem Bozkurt Chiadi Ericson Ndumele Virend K Somers American Heart Association Council on Clinical Cardiology; Council on Peripheral Vascular Diseas Source Type: research
Combined brain/heart magnetic resonance imaging in antiphospholipid syndrome-two sides of the same coin
AbstractAntiphospholipid syndrome (APS) is an autoimmune disorder characterized by arterial, venous, and/or small vessel thrombosis, pregnancy morbidity, and persistently elevated levels of antiphospholipid antibodies (aPL). Cardiovascular disease (CVD) in APS can present as heart valvular disease (HVD), macro-micro-coronary artery disease (CAD), myocardial dysfunction, cardiac thrombi, or pulmonary hypertension. Brain disease presents as stroke or transient ischemic attack (TIA) and less frequently as cerebral venous thrombosis, seizures, cognitive dysfunction, multiple sclerosis (MS) −like syndrome, or chorea. Infarcts...
Source: Clinical Rheumatology - June 10, 2021 Category: Rheumatology Source Type: research
Metalloproteinases and Their Inhibitors Are Associated with Pulmonary Arterial Stiffness and Ventricular Function in Pediatric Pulmonary Hypertension
Am J Physiol Heart Circ Physiol. 2021 Jun 4. doi: 10.1152/ajpheart.00750.2020. Online ahead of print.ABSTRACTDisturbed balance between matrix metalloproteinases (MMPs) and their respective tissue inhibitors (TIMPs) is a well-recognized pathophysiologic component of pulmonary arterial hypertension (PAH). Both classes of proteases have been associated with clinical outcomes as well as with specific pathologic features of ventricular dysfunction and pulmonary arterial remodeling. The purpose of this study was to evaluate the circulating levels of MMPs and TIMPs in children with PAH undergoing the same day cardiac MRI and righ...
Source: American Journal of Physiology. Heart and Circulatory Physiology - June 4, 2021 Category: Physiology Authors: Michal Schafer D Dunbar Ivy Kathleen Nguyen Katie L Boncella Benjamin S Frank Gareth J Morgan Kathleen Miller-Reed Uyen Truong Kelley L Colvin Michael E Yeager Source Type: research
